dobutamine hydrochloride injection, solution
physicians total care, inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride 400 mg in 100 ml - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextros
dbl dobutamine 250mg/20ml (as hydrochloride) injection
pfizer australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections - dobutamine hydrochloride injection is indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.
dobutamine injection, solution
hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.
dobutamine injection, solution
hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath
dobutamine-claris dobutamine (as hydrochloride) 250 mg/ 20 ml concentrated solution for injection ampoule
baxter healthcare pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.???
dobutamine 250mg/50ml solution for infusion vials
hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 5mg/1ml
hospira dobutamine 12.5 mg/ml sterile concentrate 250 mg/20 ml vial
hospira australia pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - dobutamine is indicated for adults who require inotropic support in the treatment of low output cardiac failure associated with organic heart disease, myocardial infarction, open heart surgery, cardiomyophathies, septic shock and cardiogenic shock. dobutamine can increase or maintain cardiac output during positive end expiratory pressure ventilation.
dbl™ dobutamine hydrochloride
pfizer new zealand limited - dobutamine hydrochloride 12.5 mg/ml - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 12.5 mg/ml excipient: sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. (refer to the data sheet for conditions which may precipitate such situations).
linezolid kabi linezolid 600 mg/300 ml solution for injection infusion bottle
fresenius kabi australia pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: sodium citrate; sodium hydroxide; glucose monohydrate; citric acid; hydrochloric acid; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram-positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.
linezolid kabi linezolid 600 mg/300 ml solution for injection infusion bag
fresenius kabi australia pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium citrate; citric acid; sodium hydroxide; water for injections; glucose monohydrate - linezolid is indicated for the treatment of suspected or proven infections due to gram-positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.